William J. Gradishar, MD, and Mark E. Robson, MD, on HER2-Negative Breast Cancer: Results From the OlympiAD Trial

Posted: Thursday, June 15, 2017

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and Mark E. Robson, MD, of Memorial Sloan Kettering Cancer Center, discuss phase III study findings on olaparib monotherapy vs chemo for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation.